Newsletter Life Sciences Voice Top Five Newsletter

Life Sciences Voice Top Five Newsletter


This week we delve into the latest happenings in the pharma sector with Merck & Ginkgo’s $490M Biologics partnership, Novartis’ BTK Inhibitor receiving the coveted FDA greenlight but raising concerns for competitor drugs, results from Novo’s Cardiovascular therapy trial, and other top news!

Merck and Ginkgo Partner for $490 Million to Enhance Biologics Manufacturing Efficiency

Merck has formed a $490 million partnership with Ginkgo Bioworks to advance biologics manufacturing efficiency. The collaboration aims to develop a more streamlined and cost-effective approach to producing biologic drugs. Ginkgo’s platform, which involves designing custom microorganisms for various applications, will be utilized to optimize the manufacturing process. The partnership seeks to address challenges in biologics production and could lead to significant improvements in drug manufacturing processes.

Approval of Novartis BTK Inhibitor Raises Concerns About Dupixent’s Risks

The approval of Novartis’ Bruton’s tyrosine kinase (BTK) inhibitor has sparked concerns about potential risks for Dupixent, a drug developed by Sanofi and Regeneron. Dupixent, used to treat conditions like eczema and asthma, may face competition from Novartis’ BTK inhibitor in treating autoimmune diseases. While BTK inhibitors have shown promise, there are worries about their safety profile. The approval’s impact on Dupixent’s market share and safety comparisons between the two drugs are subjects of interest.

Hims & Hers Plans Weight Reduction Company Launch by Year-End

Hims & Hers, a telehealth company, is anticipating the establishment of a weight reduction-focused business by the end of the year. The new initiative will provide personalized solutions for weight management, combining medical expertise and digital health tools. Hims & Hers aims to address the growing demand for accessible and effective weight loss programs, offering convenience through their online platform. The move represents the company’s expansion into broader healthcare services beyond its initial focus.

Sage to Scale Down Following Rejection of Zuranolone for MDD

Sage Therapeutics is expected to undergo downsizing and project scaling following the FDA’s rejection of zuranolone as a treatment for major depressive disorder (MDD). The decision raises uncertainty about the drug’s future prospects and leaves Sage with plans to reduce its workforce. Despite positive results in some trials, the FDA’s concerns over efficacy and dosing led to the rejection. The setback highlights the challenges of developing treatments for mental health disorders and the subsequent impact on the company’s strategic plans.

Novo’s Wegovy Shows Promise in Phase 3 Cardiovascular Risk Reduction Trial

Novo Nordisk’s Wegovy has demonstrated success in reducing the risk of cardiovascular events in a Phase 3 trial. Wegovy is a GLP-1 receptor agonist designed for weight management. The trial’s positive results reveal its potential to not only aid weight loss but also address cardiovascular risks in individuals with obesity or overweight. This marks a significant advancement in the treatment landscape for obesity-related complications, potentially leading to improved health outcomes for patients at risk of heart-related issues.

Exclusive Sponsor: Axtria – the leading global provider of cloud software and data analytics solutions to the life sciences industry.

+ posts

Latest news

Revvity introduces advanced preclinical imaging tech for scientists to make breakthroughs

Revvity, Inc. is ushering in a new era of innovation in the realm of preclinical research by...

European Commission Approves Updated Pfizer-BioNTech Vaccine for Omicron XBB.1.5 Variant

The European Commission has recently achieved a significant milestone in the ongoing battle against COVID-19 in preparation...

NICE gives Chiesi’s Elfabrio go ahead

Chiesi has recently garnered a favorable recommendation from the National Institute for Health and Care Excellence (NICE)...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you